Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorAlijotas-Reig, Jaume-
Autor(es): dc.creatorEsteve-Valverde, Enrique-
Autor(es): dc.creatorBelizna, Cristina-
Autor(es): dc.creatorSelva-O'Callaghan, Albert-
Autor(es): dc.creatorPardos-Gea, Josep-
Autor(es): dc.creatorQuintana, Angela-
Autor(es): dc.creatorMekinian, Arsene-
Autor(es): dc.creatorAnunciacion-Llunell, Ariadna-
Autor(es): dc.creatorMiró-Mur, Francesc-
Data de aceite: dc.date.accessioned2026-02-09T12:48:04Z-
Data de disponibilização: dc.date.available2026-02-09T12:48:04Z-
Data de envio: dc.date.issued2020-06-17-
Data de envio: dc.date.issued2020-06-17-
Data de envio: dc.date.issued2020-07-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41465-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S1568997220301312-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1168534-
Descrição: dc.descriptionSevere Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called “cytokine storm”. The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceAutoimmunity Reviews-
Palavras-chave: dc.subjectAcute Respiratory Distress Syndrome (ARDS)-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectCytokine storm-
Palavras-chave: dc.subjectImmunosuppressive-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Título: dc.titleImmunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.